138PD: Impact of dose adjustment on the safety and efficacy of afatinib in patients (pts) with advanced EGFR mutation-positive non-small cell lung cancer (NSCLC): Post-hoc analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)
Journal
Journal of Thoracic Oncology
Journal Volume
11
Journal Issue
4
Pages
S116-S117
Date Issued
2016
Author(s)
SDGs
Other Subjects
afatinib; epidermal growth factor receptor; acne; advanced cancer; Article; controlled study; diarrhea; drug blood level; drug dose reduction; drug efficacy; drug safety; drug tolerability; EGFR gene; gene mutation; human; major clinical study; nail disease; non small cell lung cancer; post hoc analysis; priority journal; progression free survival; rash; stomatitis; unspecified side effect
Publisher
Elsevier Inc
Type
journal article